DURECT Corporation (DRRX) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
DRRX Insider Trading Activity
DRRX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About DURECT Corporation
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Insider Activity of DURECT Corporation
Over the last 12 months, insiders at DURECT Corporation have bought $0 and sold $0 worth of DURECT Corporation stock.
On average, over the past 5 years, insiders at DURECT Corporation have bought $136,377 and sold $343,993 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 9,412 shares for transaction amount of $8,000 was made by Robertson Judith J. () on 2022‑08‑18.
List of Insider Buy and Sell Transactions, DURECT Corporation
| 2022-08-18 | Robertson Judith J. | 9,411.76 0.0041% | $0.85 | $8,000 | -41.06% | |||
| 2022-08-17 | Robertson Judith J. | 8,130 0.0035% | $0.85 | $6,906 | -42.30% | |||
| 2022-08-12 | Maderis Gail J | 25,204 0.0101% | $0.71 | $17,993 | -35.26% | |||
| 2022-08-09 | Maderis Gail J | 79,693 0.037% | $0.69 | $54,661 | -22.00% | |||
| 2022-05-26 | Robertson Judith J. | 65,000 0.0285% | $0.39 | $25,597 | +30.77% | |||
| 2022-05-24 | AZAB MOHAMMAD | 5,000 0.0021% | $0.39 | $1,950 | +26.50% | |||
| 2022-05-16 | Farfel Gail M | 29,911 0.0142% | $0.41 | $12,201 | +31.58% | |||
| 2022-05-16 | AZAB MOHAMMAD | 1,800 0.0009% | $0.42 | $758 | +31.58% | |||
| 2022-05-11 | Farfel Gail M | 9,250 0.0041% | $0.40 | $3,700 | +25.00% | |||
| 2022-05-10 | Farfel Gail M | 2,339 0.001% | $0.41 | $950 | +19.05% | |||
| 2022-05-09 | Farfel Gail M | 4,250 0.0019% | $0.40 | $1,679 | +28.21% | |||
| 2022-03-14 | Robertson Judith J. | 200,000 0.0937% | $0.59 | $118,000 | -6.36% | |||
| 2021-12-10 | Sale | Sussman Norman | Chief Medical Officer | 9,000 0.0041% | $1.05 | $9,495 | -45.10% | |
| 2021-12-07 | BENITO SIMON X | director | 20,000 0.009% | $1.02 | $20,360 | -43.00% | ||
| 2021-05-14 | Sale | Joice Judy R | Sr. VP Operations & Corp QA | 60,137 0.0003% | $1.72 | $103,682 | -34.01% | |
| 2020-09-01 | Sale | Bleichroeder LP | 10 percent owner | 250,000 0.0012% | $1.68 | $420,000 | +6.89% | |
| 2020-06-03 | Sale | Joice Judy R | Sr. VP Operations & Corp QA | 22,956 0.0001% | $2.45 | $56,284 | -18.16% | |
| 2020-05-26 | Sale | Bleichroeder LP | 10 percent owner | 39,388 0.0002% | $2.50 | $98,525 | -24.06% | |
| 2020-02-06 | Bleichroeder LP | 10 percent owner | 75,000 0.0004% | $1.65 | $123,623 | +23.31% | ||
| 2020-02-05 | Bleichroeder LP | 10 percent owner | 74,998 0.0004% | $1.69 | $126,777 | +18.24% |
Insider Historical Profitability
| First Eagle Investment Management, LLC | 10 percent owner | 26476546 85.2927% | $17.45M | 2 | 0 | +227.59% |
| Bleichroeder LP | 10 percent owner | 26414656 85.0933% | $17.41M | 3 | 2 | +19.47% |
| 21 APRIL FUND, LTD. | 10 percent owner | 22381546 72.1009% | $14.75M | 11 | 0 | +15.15% |
| THEEUWES FELIX | Chairman and CSO | 3396314 10.941% | $2.24M | 20 | 0 | +41.12% |
| SCHRECK THOMAS A | Chief Financial Officer | 1865000 6.008% | $1.23M | 2 | 0 | +101.37% |
| Robertson Judith J. | 356132 1.1473% | $234,690.83 | 4 | 0 | <0.0001% | |
| HOFFMANN DAVE | director | 248000 0.7989% | $163,432.00 | 3 | 0 | +6.97% |
| Maderis Gail J | 200000 0.6443% | $131,800.00 | 2 | 0 | <0.0001% | |
| SAXE JON S | director | 150000 0.4832% | $98,850.00 | 8 | 0 | +101.53% |
| BENITO SIMON X | director | 105000 0.3383% | $69,195.00 | 6 | 0 | +19.36% |
| Farfel Gail M | 100000 0.3221% | $65,900.00 | 4 | 0 | +25.96% | |
| BROWN JAMES E | President & CEO | 80000 0.2577% | $52,720.00 | 6 | 1 | +22.33% |
| AZAB MOHAMMAD | 60000 0.1933% | $39,540.00 | 2 | 0 | +29.04% | |
| CHAN TAI WAH | VP Pharma. Research & Develp. | 51371 0.1655% | $33,853.49 | 0 | 1 | |
| Neukermans Armand | director | 38000 0.1224% | $25,042.00 | 5 | 0 | +21.62% |
| Joice Judy R | Sr. VP Operations & Corp QA | 34832 0.1122% | $22,954.29 | 0 | 2 | |
| TAYLOR MICHAEL J | VP, Non Clinical Research | 24988 0.0805% | $16,467.09 | 0 | 2 | |
| Arenberg Michael | Chief Financial Officer | 24426 0.0787% | $16,096.73 | 1 | 0 | +110.63% |
| HOGAN MATTHEW J | Chief Financial Officer | 10000 0.0322% | $6,590.00 | 1 | 0 | +12.37% |
| Blaschke Terrence F | director | 3000 0.0097% | $1,977.00 | 2 | 0 | <0.0001% |
| LIU JEAN I | Sr. VP & General Counsel | 0 0% | $0 | 0 | 1 | |
| Sussman Norman | Chief Medical Officer | 0 0% | $0 | 0 | 1 |
Historical Insider Profitability vs. Competitors
$2,051,022 | 1591 | -12.84% | $77.66M | |
DURECT Corporation (DRRX) | $22,899,264 | 81 | 34.90% | $20.46M |
$218,350,131 | 64 | 16.68% | $154.73M | |
$125,860,243 | 57 | -4.48% | $36.57M | |
$2,740,482 | 50 | 9.37% | $37.66M | |
$30,209,812 | 45 | -1.91% | $17.59M | |
$6,021,989 | 30 | -0.17% | $227.44M | |
$3,140,759 | 30 | 10.79% | $14.24M | |
$423,174,478 | 29 | -7.58% | $22.45M | |
$1,507,654 | 22 | -23.16% | $95.7M | |
$25,034,841 | 20 | 9.38% | $110.71M | |
$934,616 | 12 | 74.76% | $790,683.00 | |
$758,061 | 9 | 60.03% | $146.12M | |
$4,039,981 | 8 | -3.44% | $13.34M | |
$8,171,353 | 7 | -14.29% | $8.08M | |
$103,523 | 3 | 9.40% | $58.3M | |
$999,999 | 1 | -52.42% | $16.42M | |
$10,000 | 1 | -96.58% | $4.94M | |
$5,003,136 | 1 | -14.58% | $257.33M |
DRRX Institutional Investors: Active Positions
| Increased Positions | 17 | +35.42% | 351,668 | +4.9% |
| Decreased Positions | 16 | -33.33% | 546,037 | -7.6% |
| New Positions | 3 | New | 38,314 | New |
| Sold Out Positions | 7 | Sold Out | 60,125 | Sold Out |
| Total Postitions | 49 | +2.08% | 7M | -2.71% |
DRRX Ownership Change vs Market
Institutional Investor Ownership
| Ingalls & Snyder Llc | $951.00 | 5.13% | 1.59M | -393,767 | -19.84% | 2024-12-31 |
| Richmond Brothers, Inc. | $805.00 | 4.34% | 1.35M | +65,230 | +5.09% | 2025-03-31 |
| Vanguard Group Inc | $681.00 | 3.67% | 1.14M | 0 | 0% | 2024-12-31 |
| Gagnon Securities Llc | $240.00 | 1.3% | 402,013 | +8,151 | +2.07% | 2024-12-31 |
| Geode Capital Management, Llc | $197.00 | 1.06% | 328,991 | +9,086 | +2.84% | 2024-12-31 |
| Montchanin Asset Management, Llc | $185.00 | 1% | 310,118 | +6,086 | +2% | 2024-12-31 |
| Beirne Wealth Consulting Services, Llc | $177.00 | 0.96% | 296,350 | -29,525 | -9.06% | 2025-03-31 |
| Blackrock, Inc. | $168.00 | 0.91% | 280,818 | 0 | 0% | 2025-03-31 |
| Dalton Investments, Inc. | $147.00 | 0.79% | 245,000 | +20,000 | +8.89% | 2024-12-31 |
| Ironwood Investment Management Llc | $103.00 | 0.55% | 171,832 | -405 | -0.23% | 2024-12-31 |